摘要
目的探讨PD1抗体联合紫杉醇化疗治疗小鼠乳腺癌的效果。方法应用小鼠乳腺癌细胞系D2F2皮下注射构建Balb/c小鼠乳腺癌模型。实验分为对照组、紫杉醇组、PD-1抗体组和PD-1抗体联合紫杉醇组,分别用PBS、紫杉醇、PD-1抗体、PD-1抗体联合紫杉醇处理小鼠。测定各组小鼠肿瘤生长曲线、生存率以及质量,同时用流式细胞仪检测小鼠肿瘤微环境以及脾脏中CD8+T细胞产生IFN-γ的变化,从而评价各组治疗效果。结果不同组荷瘤小鼠脾脏中CD8+T细胞产生IFN-γ的变化是PD1抗体处理组与PBS处理组相比差异有统计学意义(P=0.025)。PD-1抗体联合紫杉醇处理组与PBS处理组相比差异有统计学意义(P=0.003 2)。PD1抗体处理组与联合用药组相比差异有显著统计学意义(P=0.008 5)。另外,不同组荷瘤小鼠肿瘤微环境中CD8+T细胞产生IFN-γ的变化是联合用药组与PBS处理组相比差异有统计学意义(P=0.009 2)。联合用药组与紫杉醇组相比差异有统计学意义(P=0.010 9)。PD1抗体处理组与联合用药组相比差异有显著统计学意义(P=0.039)。把不同组荷瘤小鼠的生长曲线比较得出,PD1抗体治疗组与PBS组相比差异有统计学意义(P=0.004 0);PD-1抗体联合紫杉醇治疗组与紫杉醇治疗组相比差异有统计学意义(P=0.029 8)。其生存率比较,发现PD1抗体治疗组与联合用药组相比差异有统计学意义(P<0.000 1);紫杉醇组与联合用药组相比差异有统计学意义(P<0.000 1)。结论 PD1抗体联合紫杉醇治疗显著增强小鼠乳腺癌治疗效果。本研究为乳腺癌的临床治疗提供理论及实验基础。
This study was performed to investigate the therapeutic effect of PD1 antibody combined with paclitaxel chemotherapy on breast cancer in mice.Balb/c mouse breast cancer model was constructed by subcutaneous injection of mouse breast cancer cell line D2F2,and divided into control group,paclitaxel group,PD-1 antibody group and PD-1 antibody combined with paclitaxel group,which were treated with PBS,paclitaxel,PD-1 antibody and PD-1 antibody plus paclitaxel,respectively.The tumor growth curve,survival rate and weight of mice in each group were measured;the changes of IFN-γproduced by CD8+T cells in tumor microenvironment and the spleen were detected by flow cytometry.Data showed that the changes of IFN-γfrom CD8+T cells in the spleen of different tumor-bearing mice groups was different,and found that the IFN-γchanges of the PD1 antibody-treated group,PD1 antibody plus paclitaxel treatment group was statistically significant in comparison to the PBS-treated group,and the difference between PD1 antibody plus paclitaxel treatment group and PD1 antibody-treated group was also statistically significant.In addition,the changes of IFN-γproduced by CD8+T cells in the tumor microenvironment were significantly difference between the combination group and the paclitaxel group or PD1 antibody-treated group.The tumor growth curves of tumor-bearing mice in PD1 antibody treatment group and the PBS group was significantly deferent,and the difference between the PD1 antibody plus paclitaxel treatment group and the paclitaxel treatment group was statistically significant.Furthermore,the survival rate of mice in PD1 antibody plus paclitaxel treatment group was significantly different to that of PD1 antibody treatment group and the paclitaxel group.In conclusion,the treatment of PD1 antibody combined with paclitaxel significantly enhances the therapeutic effect in breast cancer mice,which provides a theoretical and experimental basis for the clinical treatment of breast cancer.
作者
张福明
朱春凯
孙晓芳
许泼实
ZHANG Fuming;ZHU Chunkai;SUN Xiaofang;XU Poshi(Clinical Laboratory of Henan Provincial People’s Hospital,Zhengzhou 450003,China)
出处
《免疫学杂志》
CAS
CSCD
北大核心
2019年第10期874-878,共5页
Immunological Journal
基金
2016年河南省医学科技攻关计划(201602261)
